IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Rhea-AI Summary

IceCure (Nasdaq: ICCM) received a 180-day Nasdaq extension, until November 9, 2026, to regain compliance with the $1.00 minimum bid price requirement.

The company continues to meet all other Nasdaq Capital Market listing criteria, and its shares remain listed and trading under the symbol ICCM.

Positive

• Nasdaq grants additional 180 days, until November 9, 2026, for bid compliance
• Company currently meets all other Nasdaq Capital Market listing requirements
• ICCM shares remain listed and trading on Nasdaq Capital Market

Negative

• Company remains non-compliant with Nasdaq $1.00 minimum bid price rule
• Potential need for reverse share split mentioned to cure bid price deficiency
• Ongoing risk tied to satisfying Nasdaq bid price criteria by November 9, 2026

News Market Reaction – ICCM

+1.69%

3 alerts

+1.69% Session close to close

+8.3% Peak Tracked

-3.5% Trough Tracked

$19.48M Market Cap

0.0x Rel. Volume

In the May 14 session, ICCM gained 1.69%, reflecting a mild positive market reaction. Argus tracked a peak move of +8.3% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement confirms Nasdaq granted IceCure a 180-day extension, until November 9, 2026, to re...

Analysis

This announcement confirms Nasdaq granted IceCure a 180-day extension, until November 9, 2026, to regain compliance with the $1.00 minimum bid price rule, with no immediate impact on listing or trading. It follows earlier steps such as seeking reverse split authority and using its effective Form F-3/A shelf and ATM program. Investors may watch progress toward the bid requirement alongside future financings and operational updates.

Key Figures

Extension length: 180 days New compliance deadline: November 9, 2026 Minimum bid price: $1.00 per share +3 more

6 metrics

Extension length 180 days Additional Nasdaq compliance period to regain minimum bid price

New compliance deadline November 9, 2026 Final date to regain compliance with Nasdaq minimum bid rule

Minimum bid price $1.00 per share Nasdaq Capital Market minimum bid price requirement

Initial compliance period 180 calendar days First window ending May 11, 2026

Required bid streak 10 consecutive business days Minimum period closing bid must be at least $1.00

Possible extended streak More than 10 up to 20 days Discretionary longer period Nasdaq may require

Historical Context

5 past events · Latest: May 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 12	Q1 2026 earnings	Positive	+0.0%	Revenue and gross profit rose on stronger North America ProSense® sales.
May 06	Earnings call notice	Neutral	-6.6%	Announcement of date and access details for Q1 2026 results call.
Apr 21	Revenue & conference	Positive	-3.3%	Preliminary U.S. ProSense® revenue up 30%+ and SBI 2026 participation.
Mar 26	Registered direct offering	Negative	-33.7%	Priced $4.0M share offering at $0.50 with Series B/C warrants.
Mar 25	Clinical trial update	Positive	-3.4%	ICESECRET kidney trial showed 83.9–89.4% recurrence-free rates over 5 years.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Positive commercial or clinical updates have often met flat or negative reactions, while dilutive financing aligned with a sharp drop.

Recent Company History

Over the last few months, IceCure reported improving fundamentals, including Q1 2026 revenue of $911,000 (up 26% year-over-year) and strong U.S. ProSense® growth, plus positive kidney cancer cryoablation data from the ICESECRET study. However, a $4.0 million registered direct offering with associated warrants led to a steep negative price reaction. Against this backdrop, today’s Nasdaq bid-price compliance extension follows prior steps like a proposed reverse split to support continued listing.

Key Terms

nasdaq capital market, minimum bid price rule, reverse share split, closing bid price

4 terms

nasdaq capital market regulatory

"will continue to trade on the Nasdaq Capital Market under the symbol "ICCM.""

The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.

minimum bid price rule regulatory

"to regain compliance with Nasdaq's minimum bid price rule."

A minimum bid price rule is a stock market requirement that a listed company's share must trade above a set minimum price over a specified period to remain listed on an exchange. It matters to investors because falling below that threshold can trigger warnings, potential delisting, and reduced liquidity—similar to a student needing a passing grade to stay enrolled—making the shares harder to buy, sell, or value accurately.

reverse share split financial

"its intention to cure the deficiency... by effecting a reverse share split."

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

closing bid price financial

"If at any time before November 9, 2026, the closing bid price of the Company's ordinary shares"

The closing bid price is the last price that a buyer was willing to pay for a security at the end of the trading day. It reflects the final visible demand for the stock — like the last offer someone makes for a used car before a yard closes — and helps investors gauge market interest, set valuations, and mark portfolios to market for that day.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

No Immediate Effect on Nasdaq Listing or Trading of the Company's Ordinary Shares

CAESAREA, Israel, May 13, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has received a notification letter from Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until November 9, 2026 to regain compliance with Nasdaq's minimum bid price rule.

Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period and if necessary, by effecting a reverse share split.

In a notification letter dated November 12, 2025, Nasdaq had first informed the Company that, based on the previous 30 consecutive business days, the Company's ordinary shares no longer met the minimum $1.00 bid price per share requirement and in accordance with Nasdaq's Listing Rules, the Company was provided 180 calendar days, or until May 11, 2026, to regain compliance. The Company did not regain compliance with the minimum $1.00 bid price per share requirement during the first 180-calendar-day compliance period and submitted a written request to the Nasdaq's staff to afford it an additional 180-day compliance period to cure the deficiency, which it was granted in a notification letter dated May 12, 2026.

If at any time before November 9, 2026, the closing bid price of the Company's ordinary shares is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. However, Nasdaq may, in its discretion, require the Company's ordinary shares to maintain a bid price of at least $1.00 for a period in excess of ten consecutive business days, but generally no more than 20 consecutive business days, before determining that the Company has demonstrated an ability to maintain long-term compliance.

This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's ordinary shares, which will continue to trade on the Nasdaq Capital Market under the symbol "ICCM."

About IceCure Medical

IceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective option to surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. 

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, IceCure is using forward-looking statements when it discusses regaining compliance with Nasdaq's continued listing requirements, and the timing and effect thereof as well as potentially effecting a reverse share split. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on IceCure's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of IceCure could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in IceCure's Annual Report on Form 20-F filed with the SEC on March 17, 2026, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, IceCure disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:

Email: investors@icecure-medical.com
Michael Polyviou 
Phone: 732-232-6914

Logo - https://mma.prnewswire.com/media/2319310/IceCure_Medical_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/icecure-granted-180-day-extension-by-nasdaq-to-regain-compliance-with-minimum-bid-requirement-302771474.html

SOURCE IceCure Medical

FAQ

What did IceCure (ICCM) announce about its Nasdaq listing on May 13, 2026?

IceCure announced that Nasdaq granted a further 180-day period, until November 9, 2026, to regain compliance with the $1.00 minimum bid price rule, according to IceCure. The company’s ordinary shares continue trading on the Nasdaq Capital Market under ticker ICCM.

What is the new Nasdaq minimum bid price compliance deadline for ICCM stock?

The new deadline for IceCure to regain compliance with Nasdaq’s $1.00 minimum bid price rule is November 9, 2026, according to IceCure. Compliance requires a closing bid of at least $1.00 for at least 10 consecutive business days.

Does the Nasdaq extension affect current trading of IceCure (ICCM) shares?

The Nasdaq extension does not immediately affect trading; IceCure’s ordinary shares continue to trade on the Nasdaq Capital Market under ICCM, according to IceCure. The matter relates only to future compliance with the $1.00 minimum bid price requirement.

What must IceCure (ICCM) do to regain Nasdaq minimum bid price compliance?

To regain compliance, IceCure’s closing bid price must be at least $1.00 per share for a minimum of 10 consecutive business days before November 9, 2026, according to IceCure. Nasdaq may require up to 20 consecutive business days in its discretion.

Why did IceCure (ICCM) receive a second 180-day Nasdaq compliance period?

IceCure received a second 180-day period because it met all other Nasdaq Capital Market listing requirements and notified Nasdaq of its intent to cure the bid price deficiency, potentially via a reverse share split, according to IceCure.

Could IceCure (ICCM) use a reverse share split to meet Nasdaq rules?

IceCure has indicated it may use a reverse share split, if necessary, to address the $1.00 minimum bid price deficiency, according to IceCure. This option is part of its plan to cure the issue during the extended compliance period.